Voluntary workplace genomic testing: wellness benefit or Pandora’s box?' by Kunal Sanghavi, Betty Cohn, Anya E. R. Prince, W. Gregory Feero, Kerry A. Ryan, Kayte Spector-Bagdady Wendy R. Uhlmann, Charles Lee, J. Scott Roberts and Debra J. H. Mathews in (2022) 7(5) npj Genomic Medicine comments
Consumer interest in genetic and genomic testing is growing rapidly, with more than 26 million Americans having purchased direct-to-consumer genetic testing services. Capitalizing on the increasing comfort of consumers with genetic testing outside the clinical environment, commercial vendors are expanding their customer base by marketing genetic and genomic testing services, including testing for pharmacogenomic and pathogenic variants, to employers for inclusion in workplace wellness programs. We describe the appeal of voluntary workplace genomic testing (wGT) to employers and employees, how the ethical, legal, and social implications literature has approached the issue of genetic testing in the workplace in the past, and outline the relevant legal landscape. Given that we are in the early stages of development of the wGT market, now is the time to identify the critical interests and concerns of employees and employers, so that governance can develop and evolve along with the wGT market, rather than behind it, and be based on data, rather than speculative hopes and fears.
